Literature DB >> 7459847

Protein-associated DNA breaks and DNA-protein cross-links caused by DNA nonbinding derivatives of adriamycin in L1210 cells.

M Levin, R Silber, M Israel, A Goldfeder, V K Khetarpal, M Potmesil.   

Abstract

The effects of Adriamycin derivatives on L1210 mouse leukemia cells were studied with the DNA alkaline elution assay. The exposure of exponentially growing cells to approximately equitoxic concentrations of N-trifluoroacetyladriamycin-14-valerate (13.8 microM) and its metabolites, N-trifluoroacetyladriamycin (9.0 microM) and N-trifluoroacetyladriamycinol (43.7 microM), for 1 hr in vitro resulted in a high frequency of protein-associated DNA breaks and DNA-protein cross-links. These effects were comparable to those observed with Adriamycin (2.8 microM) and with adriamycinol (26.9 microM). In contrast to Adriamycin and its metabolite adriamycinol, N-trifluoroacetyladriamycin-14-valerate and its two major metabolites do not bind to DNA. Despite the absence of this direct interaction, N-trifluoroacetyladriamycin-14-valerate and its metabolites produce alterations in DNA comparable with the effects of intercalating agents. No evidence for conversion of N-trifluoroacetyladriamycin-14-valerate to Adriamycin or adriamycinol was found in L1210 cells. The similar effects on DNA macromolecules, observed between intercalating and non-DNA-binding anthracyclines, are consistent with the concept that mechanisms other than direct interaction with DNA play a role in the toxic effects of these compounds.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7459847

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vitro.

Authors:  M Israel; J M Idriss; Y Koseki; V K Khetarpal
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release.

Authors:  Pubudu M Peiris; Lisa Bauer; Randall Toy; Emily Tran; Jenna Pansky; Elizabeth Doolittle; Erik Schmidt; Elliott Hayden; Aaron Mayer; Ruth A Keri; Mark A Griswold; Efstathios Karathanasis
Journal:  ACS Nano       Date:  2012-04-13       Impact factor: 15.881

3.  Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.

Authors:  H B Niell; R F Hunter; H G Herrod; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  In vitro cytotoxic activity of lithotripter shock waves combined with adriamycin or with cisplatin on L1210 mouse leukemia cells.

Authors:  A Wilmer; S Gambihler; M Delius; W Brendel
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 5.  Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies.

Authors:  Kamila Butowska; Anna Woziwodzka; Agnieszka Borowik; Jacek Piosik
Journal:  Materials (Basel)       Date:  2021-04-22       Impact factor: 3.623

6.  Cardiac damage induced by 2-amino-3-methyl-imidazo[4,5-f]quinoline in nonhuman primates.

Authors:  U P Thorgeirsson; A Farb; R Virmani; R H Adamson
Journal:  Environ Health Perspect       Date:  1994-02       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.